Anti-PD-1 antibody drug named Sintilimab
I-SBRT-HCC-001
Phase 2 small_molecule active
Quick answer
Anti-PD-1 antibody drug named Sintilimab for Stage IV HCC is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Stage IV HCC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active